Ned Biosystems, a Cambridge, Massachusetts-based, clinical-stage biotech company developing an oral oncologic combination treatment, raised over $2m toward its Series B round of financing.
Investors included Benjamin Griswold IV, Chairman of Brown Advisory, an independent Baltimore-based investment firm.
The funds raised to date will allow the company to initiate a Phase 2 clinical trial by early 2019 of NED-170, an investigational, oral combination therapy dosed daily, for both rare and common cancers.
The funding brings NED Biosystems closer to achieving key development, clinical, regulatory, and early commercialization milestones.
Founded by Rebecca Lambert and led by recently appointed CEO Marc Blaustein, Biosystems is a clinical-stage biotech company developing an innovative oral cancer combination treatment that simultaneously attacks 5 cancer-driving processes.